{"id":81894,"date":"2026-05-05T16:53:56","date_gmt":"2026-05-05T11:23:56","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=81894"},"modified":"2026-05-05T16:53:58","modified_gmt":"2026-05-05T11:23:58","slug":"wockhardt-q4-results-fy26-pat-rs-166-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/","title":{"rendered":"Wockhardt Q4 Results FY26 PAT Rs 166 Crore Turnaround from Rs 25 Crore Loss Novel Antibiotics Drive Recovery"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>Wockhardt Q4 results for FY26 delivered a consolidated net profit of Rs 166 crore, a dramatic turnaround from a net loss of Rs 25 crore in Q4 FY25. The Wockhardt Q4 results total income reached Rs 1,010 crore for the quarter. EPS for Q4 FY26 stood at Rs 10.22 per share versus Rs 3.61 in Q3 FY26, confirming the scale of the quarterly improvement.<\/p>\n<p>The Wockhardt Q4 results reflect the pharmaceutical company&#8217;s ongoing business transformation driven by its novel antibiotic pipeline. Wockhardt&#8217;s WCK series of antibiotics targeting drug-resistant bacterial infections \u2014 including Zaynich (cefepime-zidebactam), Nafithromycin, and other candidates \u2014 represent a potential high-value franchise that could fundamentally re-rate the company&#8217;s earnings profile if regulatory approvals and commercial launches proceed as expected.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Wockhardt_Q4_FY26_Results_at_a_Glance\" title=\"Wockhardt Q4 FY26 Results at a Glance\">Wockhardt Q4 FY26 Results at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Key_Highlights_from_Wockhardt_Q4_FY26_Results\" title=\"Key Highlights from Wockhardt Q4 FY26 Results\">Key Highlights from Wockhardt Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Rs_166_Crore_PAT_Turnaround_is_the_Largest_Quarterly_Swing_in_Wockhardt_Q4_Results_Recent_History\" title=\"Rs 166 Crore PAT Turnaround is the Largest Quarterly Swing in Wockhardt Q4 Results Recent History\">Rs 166 Crore PAT Turnaround is the Largest Quarterly Swing in Wockhardt Q4 Results Recent History<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Novel_Antibiotic_WCK_Pipeline_is_Wockhardt_Q4_Results_Long-Term_Re-Rating_Catalyst\" title=\"Novel Antibiotic WCK Pipeline is Wockhardt Q4 Results Long-Term Re-Rating Catalyst\">Novel Antibiotic WCK Pipeline is Wockhardt Q4 Results Long-Term Re-Rating Catalyst<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#What_Drove_Wockhardt_Q4_FY26_Performance\" title=\"What Drove Wockhardt Q4 FY26 Performance\">What Drove Wockhardt Q4 FY26 Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Dividend_and_Capital_Allocation\" title=\"Dividend and Capital Allocation\">Dividend and Capital Allocation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Outlook_for_FY27\" title=\"Outlook for FY27\">Outlook for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#What_was_Wockhardt_Q4_FY26_net_profit\" title=\"What was Wockhardt Q4 FY26 net profit?\">What was Wockhardt Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#What_is_the_WCK_novel_antibiotic_pipeline\" title=\"What is the WCK novel antibiotic pipeline?\">What is the WCK novel antibiotic pipeline?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#What_drove_Wockhardt_Q4_FY26_turnaround\" title=\"What drove Wockhardt Q4 FY26 turnaround?\">What drove Wockhardt Q4 FY26 turnaround?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#What_is_the_FY27_outlook_for_Wockhardt\" title=\"What is the FY27 outlook for Wockhardt?\">What is the FY27 outlook for Wockhardt?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/wockhardt-q4-results-fy26-pat-rs-166-crore\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Wockhardt_Q4_FY26_Results_at_a_Glance\"><\/span><strong>Wockhardt Q4 FY26 Results at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Change \/ Context<\/th>\n<\/tr>\n<tr>\n<td>Q4 Consolidated PAT<\/td>\n<td>Rs 166 crore<\/td>\n<td>Turnaround from loss Rs 25 crore in Q4 FY25<\/td>\n<\/tr>\n<tr>\n<td>Q4 Total Income<\/td>\n<td>Rs 1,010 crore<\/td>\n<td>vs Rs 913 crore in Q3 FY26<\/td>\n<\/tr>\n<tr>\n<td>Q4 EPS<\/td>\n<td>Rs 10.22<\/td>\n<td>vs Rs 3.61 in Q3 FY26<\/td>\n<\/tr>\n<tr>\n<td>Key Pipeline<\/td>\n<td>WCK novel antibiotic series<\/td>\n<td>Drug-resistant bacteria treatment platform<\/td>\n<\/tr>\n<tr>\n<td>Business Recovery<\/td>\n<td>Pharma formulations improvement<\/td>\n<td>Base business supporting turnaround<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Track live Wockhardt financials, analyst ratings and peer comparisons on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Highlights_from_Wockhardt_Q4_FY26_Results\"><\/span><strong>Key Highlights from Wockhardt Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Rs_166_Crore_PAT_Turnaround_is_the_Largest_Quarterly_Swing_in_Wockhardt_Q4_Results_Recent_History\"><\/span><strong>Rs 166 Crore PAT Turnaround is the Largest Quarterly Swing in Wockhardt Q4 Results Recent History<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The swing from a Rs 25 crore loss in Q4 FY25 to a Rs 166 crore profit in the Wockhardt Q4 results represents a Rs 191 crore year-on-year quarterly improvement \u2014 one of the largest absolute turnarounds in Wockhardt&#8217;s recent listed history. This Wockhardt Q4 results improvement reflects both base formulations business recovery and potentially meaningful contributions from the novel antibiotic product portfolio as initial commercialisation revenue begins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Novel_Antibiotic_WCK_Pipeline_is_Wockhardt_Q4_Results_Long-Term_Re-Rating_Catalyst\"><\/span><strong>Novel Antibiotic WCK Pipeline is Wockhardt Q4 Results Long-Term Re-Rating Catalyst<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The WCK series of novel antibiotics in the Wockhardt Q4 results pipeline targets the critical unmet medical need of drug-resistant bacterial infections, particularly carbapenem-resistant infections that are a growing global health crisis. Regulatory approvals for these novel antibiotics in major markets including the US and EU would provide Wockhardt with premium-priced, patent-protected revenue streams that could be transformative for earnings. The Wockhardt Q4 results turnaround is an early signal that the transformation is underway.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Drove_Wockhardt_Q4_FY26_Performance\"><\/span><strong>What Drove Wockhardt Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Wockhardt Q4 results turnaround was driven by improved base pharmaceutical formulations business performance in regulated markets including the UK, Germany, and other European markets, combined with early commercial traction from novel antibiotic products where initial launches are generating revenue. Cost rationalisation across the organisation also contributed to the improved margins visible in the Wockhardt Q4 results PAT swing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_and_Capital_Allocation\"><\/span><strong>Dividend and Capital Allocation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Wockhardt Q4 results FY26 capital allocation details including any dividend recommendation should be confirmed from the company&#8217;s exchange filing. Given the company&#8217;s ongoing investment in the novel antibiotic pipeline and the early stage of commercial launch for the WCK series, capital retention for R&amp;D and regulatory affairs is likely prioritised in the current Wockhardt Q4 results period.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Outlook_for_FY27\"><\/span><strong>Outlook for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following the Wockhardt Q4 results, FY27 outlook is positive. The base formulations business recovery should sustain, and incremental novel antibiotic revenue from expanding WCK series commercial launches could provide meaningful earnings upside. Any major regulatory milestone for Zaynich in the US market would be a significant stock catalyst beyond the operational improvement visible in the Wockhardt Q4 results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Wockhardt Q4 results FY26 deliver one of the most compelling turnaround narratives of the Q4 season. PAT Rs 166 crore versus loss Rs 25 crore represents a Rs 191 crore year-on-year swing driven by base formulations recovery and novel antibiotic early commercialisation. The Wockhardt Q4 results signal that the years of investment in the WCK novel antibiotic pipeline are beginning to translate into commercial returns. FY27 monitoring should focus on WCK series regulatory approvals and launch revenues as the key re-rating catalysts.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live Q4 results tracking and expert research.<\/p>\n<p><em>Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Wockhardt_Q4_FY26_net_profit\"><\/span><strong>What was Wockhardt Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Wockhardt Q4 results FY26 reported consolidated PAT of Rs 166 crore, a dramatic turnaround from a loss of Rs 25 crore in Q4 FY25. Total income reached Rs 1,010 crore and EPS stood at Rs 10.22, compared to Rs 3.61 in Q3 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_WCK_novel_antibiotic_pipeline\"><\/span><strong>What is the WCK novel antibiotic pipeline?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Wockhardt&#8217;s WCK novel antibiotic series includes Zaynich (cefepime-zidebactam) and Nafithromycin, targeting drug-resistant bacterial infections including carbapenem-resistant bacteria. The WCK pipeline represents a potential high-value patent-protected franchise that could significantly re-rate Wockhardt&#8217;s long-term earnings profile.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drove_Wockhardt_Q4_FY26_turnaround\"><\/span><strong>What drove Wockhardt Q4 FY26 turnaround?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Wockhardt Q4 results FY26 turnaround was driven by improved base pharmaceutical formulations business performance in regulated European markets, early commercial traction from novel antibiotic products, and cost rationalisation across operations. The combination of base business recovery and new product contribution drove the Rs 191 crore year-on-year improvement.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Wockhardt\"><\/span><strong>What is the FY27 outlook for Wockhardt?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following Wockhardt Q4 results FY26, FY27 outlook is positive with base formulations sustaining recovery and incremental WCK series novel antibiotic revenue potentially adding meaningful upside. Any US FDA approval for Zaynich would be a significant catalyst. Consult a SEBI-registered advisor before investing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wockhardt Q4 results FY26: PAT Rs 166 crore \u2014 turnaround from loss Rs 25 crore in Q4 FY25. Total income Rs 1,010 crore. EPS Rs 10.22. Novel antibiotic WCK series and pharma formulations recovery.<\/p>\n","protected":false},"author":28,"featured_media":82166,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858,3983],"class_list":["post-81894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results","tag-q4-results-2026"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777980244:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Wockhardt Q4 Results FY26 PAT Rs 166 Crore Turnaround from Loss Novel Antibiotics WCK Series"],"rank_math_description":["Wockhardt Q4 results FY26: PAT Rs 166 crore turnaround from loss Rs 25 crore in Q4 FY25. Total income Rs 1,010 crore. EPS Rs 10.22. Novel antibiotic WCK pipeline and formulations business recovery analysis."],"rank_math_focus_keyword":["Wockhardt Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["82166"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10335"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/05165332\/Wockhardt-Q4-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=81894"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81894\/revisions"}],"predecessor-version":[{"id":82167,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/81894\/revisions\/82167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/82166"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=81894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=81894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=81894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}